Form 4: Alkermes Director Nancy Lurker Receives Significant Equity Compensation Awards

Alkermes plc. Director Nancy Lurker was granted non-qualified stock options and restricted stock units as part of her compensation on May 21, 2025.

Summary

• Nancy Lurker, a Director of Alkermes plc. (ALKS), received equity compensation awards on May 21, 2025.
• The awards include 13,474 non-qualified stock options with an exercise price of $30.53 per share.
• These stock options will vest and become exercisable in full on May 21, 2026, and are set to expire on May 21, 2035.
• Additionally, Ms. Lurker was granted 6,142 restricted stock units (RSUs).
• Each RSU represents a contingent right to receive one ordinary share, and these RSUs will vest in full on May 21, 2026.

Sentiment

Score: 6

Explanation: The filing reports a routine equity compensation grant to a director, which is a neutral to slightly positive event as it aligns insider interests with shareholders. It does not indicate any significant operational or financial changes or concerns.

Positives

• The granting of equity awards to Director Nancy Lurker aligns her interests with those of shareholders, as the value of these awards is directly tied to the company's stock performance.
• This is a standard practice for director compensation, indicating continued commitment from the board and a common method for incentivizing long-term value creation.

Future Outlook

This filing primarily reports past compensation grants and does not provide forward-looking statements regarding company performance, strategic outlook, or financial guidance, beyond the future vesting and expiration dates of the granted securities.

Industry Context

The granting of equity compensation, such as stock options and restricted stock units, is a common and widely accepted practice across the pharmaceutical and biotechnology industry. This method is used to attract, retain, and incentivize key personnel, including directors, by aligning their financial interests with the long-term performance and success of the company.

Comparison to Industry Standards

• The use of stock options and restricted stock units for director compensation is standard across the pharmaceutical and biotechnology sectors, comparable to compensation practices observed at peer companies like Biogen Inc. or Gilead Sciences, Inc.
• The specific volume of units and the exercise price are typically determined by a company's compensation committee, often based on factors such as company size, financial performance, and benchmarking against a defined peer group, although specific benchmarking details are not provided in this filing.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with shareholder value creation, as the awards' ultimate value is directly tied to the company's stock performance.
• Employees: While this specific filing pertains to a director, equity compensation is a common tool used across public companies to incentivize employees and foster a sense of ownership.

Next Steps

• The granted non-qualified stock options and restricted stock units are scheduled to vest on May 21, 2026.
• The non-qualified stock options will expire on May 21, 2035.

Key Dates

Keywords

Alkermes, ALKS, SEC Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Equity Compensation, Director Compensation, Beneficial Ownership